Micromet Added to Russell 3000 Index

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI), a biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases, today
announced that it was added to the Russell 3000 Index as part of the annual
reconstitution of the Russell indexes, which occurred on June 26, 2009.

"Investors recognize the Russell 3000 as an established benchmark for tracking
investment performance, market movements and market trends. We are pleased
that Micromet has been added to the Russell 3000 Index and expect that it will
increase our visibility in the investment community," said Buck Phillips,
Senior Vice President and Chief Financial Officer of Micromet.

Annual reconstitution of Russell's U.S. indexes captures the largest U.S.
stocks as of the end of May, determined by total market capitalization.
Russell determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes. The Russell 3000 also
serves as the U.S. component to the Russell Global Index, which Russell
launched in 2007.

Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. An industry-leading $4 trillion in assets currently are
benchmarked to the Russell indexes. These investment tools originated from
Russell's multi-manager investment business in the early 1980s when the
company saw the need for a more objective, market-driven set of benchmarks in
order to evaluate outside investment managers.

Total returns data for the Russell 3000 and other Russell indexes is available
at www.russell.com/Indexes/performance/default.asp.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies generated with its
proprietary BiTE(R) antibody platform, as well as conventional monoclonal
antibodies. BiTE antibodies represent a new class of antibodies that activate
the T cells of a patient's immune system to eliminate cancer cells. Five of
Micromet's antibodies are currently in clinical trials. Its BiTE antibody
blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of
patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical
trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A
second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment
of patients with solid tumors. MT110 binds to the epithelial cell adhesion
molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's
human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is
being developed under a collaboration with Merck Serono. Adecatumomab is in a
phase 2 clinical trial in colorectal carcinoma patients after complete
resection of liver metastases, and a phase 1b clinical trial evaluating
adecatumumab in combination with docetaxel for the treatment of patients with
metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as
TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1
clinical trial for the treatment of patients with cancer. MT203, a human
antibody neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in the treatment
of various inflammatory and autoimmune diseases, such as rheumatoid arthritis,
psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by
Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a
wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1
clinical trial with Micromet's glycolipid-binding human antibody MT228 for the
treatment of melanoma.
Micromet's preclinical product pipeline includes several novel BiTE antibodies
generated with its proprietary BiTE antibody platform technology. A BiTE
antibody targeting CEA for the treatment of solid tumors is being developed in
collaboration with MedImmune. In addition, Micromet has entered into an
option, collaboration and license agreement with Bayer Schering Pharma AG
under which Bayer Schering Pharma was granted an exclusive option to license a
specified BiTE antibody against an undisclosed solid tumor target. Other BiTE
antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various
stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks
and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by
such forward-looking statements. These forward-looking statements include
statements regarding the efficacy, safety and intended utilization of our
product candidates, the conduct, timing and results of future clinical trials,
and expectations of the future expansion of our product pipeline and
collaborations. You are urged to consider statements that include the words
"ongoing," "may," "will," "believes," "potential," "expects," "plans,"
"anticipates," "intends," or the negative of those words or other similar
words to be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or implied by
any forward-looking statements include the risk that product candidates that
appeared promising in early research, preclinical studies or clinical trials
do not demonstrate safety and/or efficacy in subsequent clinical trials, the
risk that encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the detailed
results of such research, preclinical study or clinical trial, the risk that
additional information relating to the safety, efficacy or tolerability of our
product candidates may be discovered upon further analysis of preclinical or
clinical trial data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated with reliance
on outside financing to meet capital requirements, and the risks associated
with reliance on collaborators, including MedImmune, Merck Serono, TRACON and
Nycomed, for the funding or conduct of further development and
commercialization activities relating to our product candidates. These factors
and others are more fully discussed in Micromet's Quarterly Report on Form
10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May
11, 2009, as well as other filings by the company with the SEC.

SOURCE Micromet, Inc.

US Media, Andrea tenBroek, or Chris Stamm, +1-781-684-0770,
micromet@schwartz-pr.com; or US Investors, Susan Noonan, +1-212-966-3650,
susan@sanoonan.com; or European Media, Ludger Wess, +49(40)8816-5964,
ludger@akampion.com; or European Investors, Ines-Regina Buth,
+49(30)2363-2768, ines@akampion.com